ANI Pharmaceuticals, Inc. today announced the launch of Indapamide tablets, 1.25mg and 2.5mg, which is used in the treatment of hypertension and swelling associated with congestive heart failure. The annual U.S. market for Indapamide tablets is approximately $9 million, per IMS Health.

Arthur S. Przybyl, ANI’s President and CEO stated, “This is the second product that we are launching from the basket of 22 previously marketed generic products that we acquired in July 2015. This launch represents yet another successful manufacturing site transfer and re-commercialization of a previously discontinued ANDA product. We will continue to leverage our U.S. based manufacturing assets as we aim to launch additional products manufactured at these sites in 2017.”

About Indapamide Tablets

Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention (swelling) associated with congestive heart failure.

About ANI

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company’s targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products.

(Source: PR Newswire)